Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Related Party Disclosures (Tables)

v3.25.0.1
Related Party Disclosures (Tables)
 12 Months Ended
Dec. 31, 2024
Disclosure of transactions between related parties [abstract]  
Summary of Transactions with Related Parties

The amounts of transactions with related parties recognized in the consolidated income statement and the related assets and liabilities are as follows:

For the year ended and at December 31, 2024

 

 

 

Revenue

 

 

Other income

 

 

Costs*

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

Parent company

 

 

 

 

 

 

 

 

 

Stevanato Holding S.r.l.

 

 

—

 

 

 

266

 

 

 

7

 

 

 

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

 

 

 

Società Agricola Stella S.r.l.

 

 

—

 

 

 

1

 

 

 

165

 

SFEM Italia S.r.l.

 

 

—

 

 

 

—

 

 

 

21

 

E & FKH Ejendomme ApS

 

 

—

 

 

 

—

 

 

 

222

 

Studio Legale Spinazzi Azzarita Troi

 

 

—

 

 

 

—

 

 

 

198

 

Fondazione Stevanato

 

 

—

 

 

 

—

 

 

 

180

 

Incog BioPharma Services Inc

 

 

5,557

 

 

 

—

 

 

 

—

 

 

* Costs include cost of sales, selling, general administrative costs and other expenses net

 

 

 

Trade
receivables

 

 

Trade
payables

 

 

Other Assets

 

 

Contract Assets

 

 

Other
Liabilities

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parent company:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stevanato Holding S.r.l.

 

 

—

 

 

 

—

 

 

 

9,216

 

 

 

—

 

 

 

22,785

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Società Agricola Stella S.r.l.

 

 

—

 

 

 

113

 

 

 

—

 

 

 

—

 

 

 

—

 

SFEM Italia S.r.l.

 

 

—

 

 

 

2

 

 

 

—

 

 

 

—

 

 

 

—

 

Studio Legale Spinazzi Azzarita Troi

 

 

—

 

 

 

29

 

 

 

—

 

 

 

—

 

 

 

—

 

Incog BioPharma Services Inc

 

 

208

 

 

 

—

 

 

 

—

 

 

 

3,628

 

 

 

3

 

 

 

For the year ended and at December 31, 2023

 

 

 

Revenue

 

 

Costs*

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

Winckler & Co. Ltd.

 

 

—

 

 

 

191

 

Società Agricola Stella S.r.l.

 

 

—

 

 

 

110

 

SFEM Italia S.r.l.

 

 

—

 

 

 

20

 

E & FKH Ejendomme ApS

 

 

—

 

 

 

435

 

Studio Legale Spinazzi Azzarita Troi

 

 

—

 

 

 

311

 

Fondazione Stevanato

 

 

—

 

 

 

240

 

C.T.S. Studio AS

 

 

—

 

 

 

21

 

Incog BioPharma Services Inc

 

 

545

 

 

 

—

 

 

* Costs include cost of sales, selling, general administrative costs and other expenses net

 

 

 

Trade
receivables

 

 

Trade
payables

 

 

Other
Assets

 

 

Other
Liabilities

 

 

 

(EUR thousand)

 

Parent company:

 

 

 

 

 

 

 

 

 

 

 

 

Stevanato Holding S.r.l.

 

 

—

 

 

 

—

 

 

 

4,020

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

 

 

 

 

 

 

Società Agricola Stella S.r.l.

 

 

—

 

 

 

102

 

 

 

—

 

 

 

—

 

Studio Legale Spinazzi Azzarita Troi

 

 

—

 

 

 

168

 

 

 

—

 

 

 

—

 

C.T.S. Studio AS

 

 

—

 

 

 

1

 

 

 

—

 

 

 

—

 

SIT Manufacturing

 

 

—

 

 

 

—

 

 

 

2,034

 

 

 

—

 

Incog BioPharma Services Inc

 

 

636

 

 

 

 

 

 

 

 

 

1,210

 

 

 

 

 

Loan from/to related parties

For the year ended and at December 31, 2023

 

 

 

Interest
received

 

 

Interest
paid

 

 

Financial
assets or
liabilities

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

 

 

 

SE Holdings Co.Ltd.

 

 

—

 

 

 

3

 

 

 

—

 

 

For the year ended December 31, 2022

 

 

 

Revenue

 

 

Costs*

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

Winckler & Co. Ltd.

 

 

—

 

 

 

313

 

Società Agricola Stella S.r.l.

 

 

—

 

 

 

90

 

SFEM Italia S.r.l.

 

 

—

 

 

 

19

 

E & FKH Ejendomme ApS

 

 

—

 

 

 

419

 

Piovesan Barbara

 

 

—

 

 

 

30

 

Studio Legale Spinazzi Azzarita Troi

 

 

—

 

 

 

384

 

Fondazione Stevanato

 

 

—

 

 

 

305

 

C.T.S. Studio AS

 

 

—

 

 

 

23

 

Incog BioPharma Services Inc

 

 

509

 

 

 

—

 

 

* Costs include cost of sales, selling, general administrative costs and other expenses net

 

Loan from/to related parties

For the year ended December 31, 2022

 

 

 

Interest
received

 

 

Interest
paid

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

Other related parties

 

 

 

 

 

 

SE Holdings Co.Ltd.

 

 

—

 

 

 

5

 

 

 

 

 

 

 

Key management personnel of the Group

 

 

 

 

 

 

Directors and Key Managers

 

 

2

 

 

 

—

 

 
Summary of Emoluments to Directors and Key Management

Emoluments to Directors and Key Management

The fees of the Directors of Stevanato Group S.p.A. are as follows:

For the year ended December 31, 2024

 

 

Fixed remuneration

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

compensation (2)

 

 

remuneration

 

 

fee

 

 

benefits (1)

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Directors

 

 

1,970

 

 

 

6

 

 

 

459

 

 

 

2,435

 

 

 

(1) Fringe benefits related to car and insurance benefits

 

(2) Shares granted to board members

 

For the year ended December 31, 2023

 

 

Fixed remuneration

 

 

Pension

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

expense (2)

 

 

compensation (3)

 

 

remuneration

 

 

fee

 

 

benefits (1)

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Directors

 

 

2,242

 

 

 

12

 

 

 

70

 

 

 

438

 

 

 

2,762

 

 

(1) Fringe benefits related to car and insurance benefits

 

(2) Pensions expense related to "Trattamento Fine Mandato" accrued in the year

(3) Shares granted to board members

For the year ended December 31, 2022

 

 

Fixed remuneration

 

 

Pension

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

expense(2)

 

 

compensation (3)

 

 

remuneration

 

 

fee

 

 

benefits (1)

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Directors

 

 

2,353

 

 

 

12

 

 

 

62

 

 

 

379

 

 

 

2,806

 

 

(1) Fringe benefits related to car and insurance benefits

 

(2) Pensions expense related to "Trattamento Fine Mandato" accrued in the year

(3) Shares granted to board members

The aggregate compensation for members of the Senior Management Team (excluding the Chairman and including the CEO) is as follows:

For the year ended December 31, 2024

 

 

 

Fixed remuneration

 

 

Variable

 

 

Pension

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

remuneration(2)

 

 

expense (3)

 

 

compensation(4)

 

 

remuneration

 

 

fee

 

 

benefits(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Key Management

 

 

1,741

 

 

 

22

 

 

 

79

 

 

 

2,325

 

 

 

719

 

 

 

4,886

 

 

(1) Fringe benefits related to car and insurance benefits

(2) Variable remuneration related to MBO

(3) Pensions expense related to "Trattamento Fine Rapporto" accrued in the year and to severance payments

(4) Shares granted under stock grant plan 2023-2027 and other share-based incentive plans

 

For the year ended December 31, 2023

 

 

Fixed remuneration

 

 

Variable

 

 

Pension

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

remuneration(2)

 

 

expense(3)

 

 

compensation(4)

 

 

remuneration

 

 

fee

 

 

benefits(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Key Management

 

 

1,777

 

 

 

28

 

 

 

94

 

 

 

94

 

 

 

845

 

 

 

2,838

 

 

(1) Fringe benefits related to car and insurance benefits

(2) Variable remuneration related to MBO

(3) Pensions expense related to "Trattamento Fine Rapporto" accrued in the year

(4) Shares granted under stock grant plan 2023-2027 and other share-based incentive plans

For the year ended December 31, 2022

 

 

Fixed remuneration

 

 

Variable

 

 

Pension

 

 

Share based

 

 

Total

 

 

 

Annual

 

 

Fringe

 

 

remuneration(2)

 

 

expense(3)

 

 

compensation(4)

 

 

remuneration

 

 

fee

 

 

benefits(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(EUR thousand)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Key Management

 

 

1,619

 

 

 

26

 

 

 

1,198

 

 

 

87

 

 

 

5,423

 

 

 

8,353

 

 

(1) Fringe benefits related to car and insurance benefits

(2) Variable remuneration related to MBO and LTI. With regard to variable compensation, key managers' performance was measured not only by financial indicators, such as revenue and EBITDA margin, but also by non-financial indicators such as (i) environment: programs in line with carbon neutrality, (ii) gender balance in senior position, (iii) quality mindset and performances and (iv) values and guiding principles.

(3) Pensions expense related to "Trattamento Fine Rapporto" accrued in the year

(4) Shares granted under stock grant plan 2021-2027 and other share-based incentive plans